Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging

EP: 1.The Evolvement of Imaging in ccRCC

EP: 2.The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses

EP: 3.Strengths and Weaknesses of Imaging Modalities in ccRCC

EP: 4.Treatment or Lack of Treatment of Small Renal Masses

EP: 5.Decision-Making in Small Renal Masses

EP: 6.Current Unmet Needs in ccRCC Diagnosis

EP: 7.Early Detection of ccRCC

EP: 8.Key Benefits of PET in ccRCC Risk Stratification

EP: 9.The ZIRCON Trial

EP: 10.The MOA of TLX250

EP: 11.Top-Line Results of the Phase 3 ZIRCON Study

EP: 12.Risk Stratification in ccRCC: The Impact in Patient Populations

Now Viewing

EP: 13.Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging

EP: 14.Overcoming Challenges for Wider Adoption of TLX250

EP: 15.The Future of PET Imaging Agents

EP: 16.The Logistical Challenges in ccRCC Treatment

Lymph Node Management and Molecular Imaging

Main Discussion Topics:

• The current approach typically limits lymph node dissection to radiographically evident disease.
• Molecular imaging could identify nodal disease missed by conventional imaging.
• Detection of nodal disease by molecular imaging would be actionable.
• Could influence surgical planning or shift patients toward systemic therapy approaches

Key Points for Physicians:

• Neither expert routinely performs lymph node dissection without radiographic indication.
• A positive node on molecular imaging would likely change management.
• Options include targeted lymph node dissection or initiation of systemic therapy.
• Improved node detection could help homogenize treatment groups in clinical trials.

Notable Insights:

Nodal disease detected by molecular imaging is considered biologically significant and likely indicates systemic disease requiring more than surgery alone.

Clinical Significance:

Molecular imaging could fundamentally change nodal staging and management decisions, potentially moving patients from surgery-first approaches to systemic therapy.